Fox Nathan S, Gupta Simi, Lam-Rachlin Jennifer, Rebarber Andrei, Klauser Chad K, Saltzman Daniel H
Maternal-Fetal Medicine Associates, PLLC, and the Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York.
Obstet Gynecol. 2016 Apr;127(4):625-630. doi: 10.1097/AOG.0000000000001300.
To evaluate cervical pessary as an intervention to prevent preterm birth in twin pregnancies with a short cervix.
This was a retrospective cohort study of twin pregnancies managed by a single maternal-fetal medicine practice from 2005 to 2015. We included patients at 28 weeks of gestation or less who were diagnosed with a cervical length less than 20 mm. At the time of diagnosis, all patients were prescribed vaginal progesterone. Starting in 2013, they were also offered pessary placement in addition to vaginal progesterone. We compared outcomes between patients who received a pessary and matched women in a control group in a one-to-three ratio. Women in the control group were matched to women in the case group according to cervical length and gestational age (within 5 mm and 1 week, respectively, of the case patient at the time of pessary placement). We excluded patients with cerclage, monochorionic-monoamniotic placentation, major fetal congenital anomalies discovered before or after birth, patients with twin-twin transfusion syndrome, and patients for whom there were no appropriate controls. Chi-square, Fisher exact, and Student's t tests were used, as appropriate. Regression analysis was performed to control for significant differences at baseline.
Twenty-one patients received a cervical pessary, and they were compared with 63 matched women in the control group. As expected (as a result of matching), baseline gestational age (25.7±2.1 compared with 25.9±2.1 weeks of gestation, P=.671) and cervical length (10.9±3.6 mm compared with 11.9±4.5 mm, P=.327) were similar between the groups. Patients with a pessary had a significantly lower incidence of delivery at less than 32 weeks of gestation (1/21 [4.8%] compared with 18/63 [28.6%], adjusted P=.05), longer interval to delivery (65.2±16.8 compared with 52.1±24.3 days, adjusted P=.025), and a lower incidence of severe neonatal morbidity (2/21 [9.5%] compared with 22/63 [34.9%], adjusted P=.04).
For twin pregnancies with a short cervix, the addition of a cervical pessary to vaginal progesterone is associated with prolonged pregnancy and reduced risk of adverse neonatal outcomes. A large randomized trial should be performed to verify these retrospective findings.
评估宫颈托作为一种干预措施,用于预防宫颈短的双胎妊娠早产。
这是一项回顾性队列研究,研究对象为2005年至2015年由单一母胎医学机构管理的双胎妊娠。我们纳入了妊娠28周及以下、宫颈长度小于20mm的患者。诊断时,所有患者均接受阴道用黄体酮治疗。从2013年开始,除阴道用黄体酮外,还为患者放置宫颈托。我们将接受宫颈托治疗的患者与对照组中按1:3比例匹配的女性进行结局比较。对照组女性根据宫颈长度和孕周(分别在放置宫颈托时与病例组患者相差5mm以内和1周以内)与病例组女性进行匹配。我们排除了接受宫颈环扎术的患者、单绒毛膜单羊膜囊胎盘的患者、出生前后发现的主要胎儿先天性异常患者、双胎输血综合征患者以及没有合适对照的患者。根据情况使用卡方检验、Fisher精确检验和Student t检验。进行回归分析以控制基线时的显著差异。
21例患者接受了宫颈托治疗,并与对照组中63例匹配的女性进行比较。正如预期的那样(由于匹配),两组之间的基线孕周(25.7±2.1周与25.9±2.1周,P = 0.671)和宫颈长度(10.9±3.6mm与11.9±4.5mm,P = 0.327)相似。接受宫颈托治疗的患者在妊娠32周前分娩的发生率显著较低(1/21 [4.8%]与18/63 [28.6%],校正后P = 0.05),分娩间隔时间更长(65.2±16.8天与52.1±24.3天,校正后P = 0.025),严重新生儿发病率较低(2/21 [9.5%]与22/63 [34.9%],校正后P = 0.04)。
对于宫颈短的双胎妊娠,在阴道用黄体酮基础上加用宫颈托可延长孕周并降低不良新生儿结局的风险。应进行一项大型随机试验以验证这些回顾性研究结果。